GLPwatch
Papers (10410)
Page 151 of 174, ranked by citation count.
- Factors influencing patient preferences for obesity pharmacotherapy: The triangulation of semi-structured interviews, photovoice study and focus group discussions.
- SEMASEARCH Study Design: Real-World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials.
- Multimodal imaging reveals distinct cardiac benefits of dulaglutide versus dapagliflozin in a mouse model of glucotoxic cardiomyopathy.
- Peptide Marriages: Modular Assembly of Multi-Agonist Therapeutics.
- Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.
- Cost-Effectiveness of Pharmacologic Therapies for Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in the United States.
- Orforglipron, quand le GLP-1 devient simple et oral.
- Aktuelles zur Therapie mit GLP-1-Rezeptoragonisten bei Patienten mit Diabetes mellitus Typ 2.
- Case study on adverse reactions of dulaglutide: literature review.
- Repairing effects of liraglutide on spinal cord injury in rats via PI3K/AKT/ENOS signaling pathway.
- Semaglutide and GLP-1 Agonists: Forensic and Medicolegal Implications.
- [GLP-1 agonist supports weight loss].
- Dose-Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis.
- Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction-Associated Steatotic Liver Disease in People With Obesity. A Systematic Review and Network Meta-Analysis of Randomised Clinical Trials.
- Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis.
- Weekly Journal Scan: Tirzepatide did not SURPASS the cardiovascular benefits of dulaglutide in type 2 diabetes.
- Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double-Blind Phase II Trial.
- Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy.
- [Liraglutide improves cardiac structure and function in mice with advanced diabetic nephropathy and massive proteinuria].
- Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trial.
- Familial partial lipodystrophy type 2 associated with a novel LMNA variant (c.604G>C; p.Glu202Gln): a Colombian family case series.
- The "microdosing" dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions.
- Lixisenatide in the treatment of Type 2 diabetes.
- In brief: Higher-dose semaglutide (Ozempic) for type 2 diabetes.
- Liraglutide versus colesevelam for treating bile acid diarrhoea - Authors' reply.
- Benchmarking size-exclusion chromatography columns for the analysis of therapeutic peptides and model oligonucleotides.
- Exploring the rates of Gastrointestinal adverse effects among five GLP-1 receptor agonists: A systematic review and Meta-Analysis of randomized controlled trials.
- Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States.
- MASH and liver fibrosis: Clinical trials to watch.
- Retrospective Comparative Study of Oral Versus Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus.
- Exenatide administration time determines the effects on blood pressure dipping in <i>db/db</i> mice via modulation of food intake and sympathetic activity.
- Association of tirzepatide with erectile dysfunction in people with type 2 diabetes.
- Prevalence of Obesity Medications in the Military Health System: An Update from 2022.
- The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model.
- Association between incretin-related drugs and fractures in patients treated with pioglitazone: A pharmacovigilance study using the FDA Adverse Event Reporting System.
- Benchmarking the medication efficiency and technological progress of diabetes drugs.
- American Society for Metabolic and Bariatric Surgery statement on the treatment options for patients with non-response and weight recurrence after metabolic and bariatric surgery.
- Adjunctive GLP1 Receptor Agonists in Patients with Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation.
- Effects of Tirzepatide on Body Composition, Metabolic Parameters, and Sleep Outcomes: A Real-World One-Year Prospective Study.
- Calories to satiation-A new predictor of anti-obesity therapy outcome?
- Association Between Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.
- Effects of exercise and liraglutide on vascular health and inflammation during weight loss maintenance: a prespecified secondary analysis of the S-LiTE trial.
- Efficacy of Tirzepatide, Retatrutide, and Semaglutide for Weight Loss in Obese Individuals Without Diabetes.
- [Optimizing treatment of type 2 diabetic patients].
- Semaglutide Inhibits Neuronal Apoptosis and Improves Cognitive Function in Mice after Traumatic Brain Injury, Mainly via the Caspase-Dependent Pathway.
- Musculoskeletal adverse events with incretin-based diabetes drugs: a FAERS pharmacovigilance study.
- Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912-1920.
- Diabetic ketoacidosis induced by liraglutide overdose for weight loss in a type 2 diabetes patient: A case report.
- Drugs and devices for weight management.
- Comment on: Semaglutide and cardiovascular outcomes in obesity without diabetes.
- [GLP-1 receptor agonists in hypertension - a new approach for difficult-to-treat blood pressure?]
- In adults with T2D and ASCVD, tirzepatide was noninferior to dulaglutide for a composite CV outcome at a median 4 y.
- Real-World Cardiovascular Outcomes of GLP-1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer.
- Implementation of the IWQOL-Lite-CT in Observational Research: Comparison of Baseline Scores With a Clinical Trial Population and Psychometric Evaluation.
- Is semaglutide a better weight-management option than bariatric surgery for patients undergoing total knee arthroplasty?
- Efficacy and Safety of Dulaglutide for Weight Reduction Among Diabetic Patients in Saudi Arabia: A Retrospective Cohort Study.
- [Peptide hormone analogue-based pharmacotherapy for obesity is effective : What is the evidence on hard end points and the long-term course?]
- Efficacy and safety of GLP-1 receptor agonists in the treatment of type 2 diabetes and/or obesity in patients with Cushing’s syndrome: a multicenter retrospective study.
- Use of GLP-1 Receptor Agonists is Associated with an Increased Rate of Upper Eyelid Blepharoplasty.
- No evidence that tirzepatide can worsen diabetic retinopathy. Reply to Fadini GP [letter]. Reassessing retinopathy risk with tirzepatide therapy. Reply to Zhang N, Wang W, Wan G [letter].